Pathogenic mutations and sequence variants within mitofusin 2 gene in Polish patients with different hereditary motor-sensory neuropathies

• Autorzy: Kotruchow K. , Kabzinska D. , Kochanski A.
• Języki publikacji: EN

Abstrakty

EN

At the time of its first description in 2004, MFN2 was considered the most frequently mutated gene in hereditary motor and sensory neuropathy type 2 (HMSN 2). However recent studies have shown that the frequency of MFN2 gene mutations in HMSN II patients is surprisingly low. To date, no systematic studies devoted to HMSN Ila in Poland have been carried out. In this study, we searched for MFN2 gene mutations in Polish patients representing the population of nearly 40 million. We decided to include a wide spectrum of clinical phenotypes in the study, proving able to detect, in a group of 67 affected patients: 1) 3 pathogenic mutations 2) 3 sequence variants of unknown pathogenic status 3) 9 rare MFN2 gene sequence variants 4) 6 common polymorphisms The frequency of MFN2 gene mutations in the whole group of patients is 4.5%. Due to the high frequency of MFN2 gene sequence variants within single patients we could not definitely exclude the cumulative effect of these contributing to the HMSN II phenotype. The MFN2 gene should therefore be considered in Polish HMSN II patients, though it is still not possible to determine its position in HMSN II molecular diagnostics.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2015
• Tom: 75
• Numer: 3
• Opis fizyczny: p.264-278,fig.,ref.

Twórcy

autor

Kotruchow K.

• Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Kabzinska D.

• Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Kochanski A.

• Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

Bibliografia

• Aarskog NK and Vedeler CA (2000) Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107: 494-498.
• Albulym OM, Zhu D, Reddel S, Kennerson M, Nicholson G (2013) The MFN2 V705I Variant Is Not a Disease- Causing Mutation: A Segregation Analysis in a CMT2 Family. J Neurodegener Dis: 1-5. Auranen M, Ylikallio E, Toppila J, Somer M, Kiuru-Enari S, Tyynismaa H (2013) Dominant GDAP1 founder mutation is a common cause of axonal Charcot-Marie-Tooth dis¬ease in Finland. Neurogenetics 14: 123-132.
• Bergamin G, Boaretto F, Briani C, Pegoraro E, Cacciavillani M, Martinuzzi A, Muglia M, Vettori A, Vazza G, Mostacciuolo ML (2014) Mutation Analysis of MFN2, GJB1, MPZ and PMP22 in Italian Patients with Axonal Charcot-Marie-Tooth Disease. Neuromolecular Med 16: 540-550.
• Braathen GJ, Sand JC, Lobato A, Hoyer H, Russell MB (2010) MFN2 point mutations occur in 3.4% of Charcot- Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 11: 48.
• Braathen GJ, Sand JC, Lobato A, Heyer H, Russel B (2011) Genetic epidemiology of Charcot-Marie-Tooth in general population. Eur J Neurol 18: 39-48.
• Brockmann K, Dreha-Kulaczewski S, Dechent P, Bonnemann C, Helms G, Kyllerman M, Bruck W, Frahm J, Huehne K, Gartner J, Rautenstrauss B (2008) Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations. J Neurol 255: 1049-1058.
• Brozkova DS, Posadka J, Lassuthova P, Mazanec R, Haberlova J, Siskova D, Sakmaryova I, Neupauerova J, Seeman P (2013) Spectrum and frequencies of mutations in the MFN2 gene and its phenotypical expression in Czech hereditary motor and sensory neuropathy type II patients. Mol Med Rep 8: 1779-1784.
• Cartoni R and Martinou JC (2009) Role of mitofusin 2 muta¬tions in the physiopathology of Charcot-Marie-Tooth disease type 2A. Exp Neurol 218: 268-273.
• Casasnovas C, Banchs I, Cassereau J, Gueguen N, Chevrollier A, Martinez-Matos JA, Bonneau D, Volpini V (2010) Phenotypic spectrum of MFN2 mutations in the Spanish population. J Med Genet 47: 249-256.
• Chapman AL, Bennett EJ, Ramesh TM, De Vos KJ, Grierson AJ (2013) Axonal Transport Defects in a Mitofusin 2 Loss of Function Model of Charcot-Marie-Tooth Disease in Zebrafish. PLoS One 8: e67276.
• Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regu¬late mitochondrial fusion and are essential for embryonic development. J Cell Biol 160: 189-200.
• de Brito OM and Scorrano L (2009) Mitofusin-2 regulates mitochondrial and endoplasmic reticulum morphology and tethering: the role of Ras. Mitochondrion 9: 222¬226.
• Del Bo R, Moggio M, Rango M, Bonato S, D'Angelo MG, Ghezzi S, Airoldi G, Bassi MT, Guglieri M, Napoli L, Lamperti C, Corti S, Federico A, Bresolin N, Comi GP (2008) Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction. Neurology 71: 1959-1966.
• Detmer SA, Vande VC, Cleveland DW, Chan DC (2008) Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot- Marie-Tooth type 2A. Hum Mol Genet 17: 367-375.
• Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen JT, Meins M (2006) Charcot-Marie-Tooth neu¬ropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet 7: 53.
• Feely SM, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, Reilly MM, Shy ME (2011) MFN2 muta¬tions cause severe phenotypes in most patients with CMT2A. Neurology 76: 1690-1696.
• Gess B, Schirmacher A, Boentert M, Young P (2013) Charcot-Marie-Tooth disease: frequency of genetic sub¬types in a German neuromuscular center population. Neuromuscul Disord 23: 647-651.
• Heyer H, Braathen GJ, Busk OL, Holla 0L, Svendsen M, Hilmarsen HT, Strand L, Skjelbred CF, Russel MB (2014) Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next generation sequencing. Biomed Res Int 2014: 210401
• Kabzinska D, Pierscinska J, Kochanski A (2009) Screening of the 17p11.2--p12 region in a large cohort of patients with Charcot-Marie-Tooth (CMT) disease or hereditary neuropathy with liability to pressure palsies (HNPP). J Appl Genet 50: 283-288.
• Khidiyatova IM, Skachkova IA, Saifullina EV, Magzhanov RV, Schagina OA, Zinchenko RA, PetrinAN, Khusnutdinova EK (2013) MFN2 gene analysis in patients with hereditary motor and sensory neuropathy from Bashkortostan Republic (in Russian). Genetika 49: 884-890.
• Klein CJ, Kimmel GW, Pittock SJ, Engelstad JE, Cunningham JM, Wu Y, Dyck PJ (2011) Large kindred evaluation of mitofusin 2 novel mutation, extremes of neurologic pre¬sentations, and preserved nerve mitochondria. Arch Neurol 68: 1295-1302.
• Kotruchow K, Kabzinska D, Hausmanowa-Petrusewicz I, Kochanski A (2013) A late-onset and mild form of Charcot-Marie-Tooth disease type 2 caused by a novel splice-site mutation within the Mitofusin-2 gene. Acta Myol 32: 166-169.
• Lawson VH, Graham BV, Flanigan KM (2005) Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 65: 197-204.
• Li M, Cheng TS, Ho PW, Chan KH, Mak W, Cheung RT, Ramsden DB, Sham PC, Song Y, Ho SL (2009) -459C>T point mutation in 5' non-coding region of human GJB1 gene is linked to X-linked Charcot-Marie-Tooth neuropa¬thy. J Peripher Nerv Syst 14: 14-21.
• Martikainen MH, Kytovuori L, Majamaa K (2014) Novel mitofusin 2 splice-site mutation causes Charcot-Marie- Tooth disease type 2 with prominent sensory dysfunction. Neuromuscul Disord 24: 360-364.
• Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010) Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton com¬plex. J Neurosci 30: 4232-4240.
• 0stern R, Fagerheim T, Hjellnes H, Nygard B, Mellgren SI, Nilssen O (2014) Segregation analysis in families with Charcot-Marie-Tooth disease allows reclassification of putative disease causing mutations. BMC Med Genet 15: 12.
• Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacin M, Zorzano A (2005) The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet 14: 1405-1415.
• Polke JM, Laura M, Pareyson D, Taroni F, Milani M, Bergamin G, Gibbons VS, Houlden H, Chamley SC, Blake J, Devile C, Sandford R, Sweeney MG, Davis MB, Reilly MM (2011) Recessive axonal Charcot-Marie- Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 77: 168-173.
• Sivera R, Sevilla T, Vilchez JJ, Martinez-Rubio D, Chumillas MJ, Vazquez JF, Muelas N, Bataller L, Millan JM, Palau F, Espinos C (2013) Charcot-Marie-Tooth disease: genet¬ic and clinical spectrum in a Spanish clinical series. Neurology 81: 1617-1625.
• Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC (2009) Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell 20: 3525-3532.
• Verhoeven K, Claeys KG, Züchner S, Schroder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van
• Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den BP, Verellen C, Van Coster R, Goemans N, Auer-Grumbach M, Robberecht W, Milic RV, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen HJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V (2006) MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129: 2093-2102.
• Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, Saito M, Tsuji S, Hayashi Y, Hirokawa N (2001) Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 105: 587-597.
• Zhu D, Kennerson ML, Walizada G, Züchner S, Vance JM, Nicholson GA (2005) Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations. Neurology 65: 496-497.
• Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas F, Bird T, Timmerman V, Shy M, Vance JM (2006) Axonal neu¬ropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59: 276-281.
• Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36: 449-451.